Lanterne Dx
Lanterne Dx is recorded as a service provider in 6 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 6 of 6 trials · Latest update first
Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Lunresertib Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors (MYTHIC Study)
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing Advanced Malignancies.
Sponsor Bicycletx Limited
- Start (EU)
- Latest update
- Estimated end
Phase 2 Study of Zelenectide Pevedotin in Participants with NECTIN4 Amplified Advanced Breast Cancer
Sponsor Bicycletx Limited
- Start (EU)
- Latest update
- Estimated end
A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors
Sponsor Elevar Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Sponsor Bicycletx Limited
- Start (EU)
- Latest update
- Estimated end
A Phase I/Ib, open-label, dose finding study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of OBT076, a CD205-directed antibody-drug conjugate, in recurrent and/or metastatic CD205-positive solid tumors
Sponsor Oxford Biotherapeutics Limited
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Lanterne Dx?
The 2026-10-09 snapshot links Lanterne Dx to 6 distinct CTIS trials. Recorded services include Laboratory services, FISH slide imaging, Histopathology. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Lanterne Dx?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Gastroenterology, Gynecology, Hepatology. Recorded phases include Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Lanterne Dx conducted?
The linked trials record locations in 19 countries, including Spain, France, Belgium, Italy, Netherlands. These are trial locations, not confirmed office locations or countries where Lanterne Dx delivered services.
What can this page tell me about Lanterne Dx's trial experience?
Browse 6 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Lanterne Dx. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Lanterne Dx LLC